<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565341</url>
  </required_header>
  <id_info>
    <org_study_id>Focus-PiQo4 Melasma-17-04</org_study_id>
    <nct_id>NCT03565341</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PiQo4 Device for Treatment of Melasma</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of the PiQo4 Picosecond Laser (PSL) System for the Treatment of Patients With Melasma: A Prospective, Randomized, Split Face Study Comparing the Added Value of 585nm Over 1064nm PSL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Focus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Focus Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, Prospective, Open Label with Split-face Study Design. Face sides will be&#xD;
      randomized to receive either 1064nm alone or 1064nm &amp; 585nm combination treatment.&#xD;
&#xD;
      Each subject will receive up to 3 treatments at monthly intervals (±4 days). Follow-up visits&#xD;
      will take place at 1, 3, and 6 months following the last treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Actual">August 8, 2019</completion_date>
  <primary_completion_date type="Actual">August 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Face sides will be randomized to receive either 1064nm alone or 1064nm &amp; 585nm combination treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects having an improvement of at least 1 point on the MSS or ≥ 50% MASI score improvement on at least one of the face sides at the 1-month follow-up visit.</measure>
    <time_frame>1 month follow up</time_frame>
    <description>The study will be deemed successful if the point estimate of the percent of successful subjects will be at least 50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects having an improvement of at least 1 point on the MSS or ≥ 50% MASI score improvement on at least one of the face sides at the 3-month follow-up visit</measure>
    <time_frame>3 months follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects having an improvement of at least 1 point on the MSS or ≥ 50% MASI score improvement on each face side</measure>
    <time_frame>6 months follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>Melasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of Melasma Using PiQo4 Laser System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiQo4</intervention_name>
    <description>PiQo4 Laser System for treatment of Melasma</description>
    <arm_group_label>Melasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy Female&#xD;
&#xD;
          2. Age= 18-75.&#xD;
&#xD;
          3. Fitzpatrick skin phototype = II-V&#xD;
&#xD;
          4. Melasma severity: diagnosed with mild to severe melasma lesions (MSS≥2)&#xD;
&#xD;
          5. Melasma type: Dermal or mixed type melasma, confirmed by Wood's lamp test&#xD;
&#xD;
          6. Melasma duration: The subject's melasma has persisted for greater than 6 months&#xD;
&#xD;
          7. Melasma previous treatments: has failed to respond to conventional treatment with&#xD;
             hydroquinone or other topical lightening agents&#xD;
&#xD;
          8. Able to read, understand and provide written Informed Consent.&#xD;
&#xD;
          9. Able and willing to comply with the treatment/follow-up schedule and post treatment&#xD;
             care&#xD;
&#xD;
         10. Agreed to use the same facial skin care products during the clinical trial period&#xD;
             (including the follow-up period)&#xD;
&#xD;
         11. Agreed to the prohibition of the use of local/systemic corticosteroids or retinoids&#xD;
             and other local/systemic lightening medications, and willing to abide by such&#xD;
             instructions&#xD;
&#xD;
         12. Agreed to the daily use of an over SPF 50 sunblock on their face during the clinical&#xD;
             trial period (including the follow-up period), and willing to abide by such&#xD;
             instructions&#xD;
&#xD;
         13. Agreed to have their face photographed and willingness to allow Focus Medical (the&#xD;
             study Sponsor) and Lumenis and the investigators to use de-identified photographs of&#xD;
             the treated area for presentation and publication purposes&#xD;
&#xD;
         14. (In case of fertile women) Tested negative in the pregnancy test and agreed to use&#xD;
             birth control contraceptives during the clinical trial period - Oral contraceptives&#xD;
             are forbidden as they may influence the results of the clinical study.&#xD;
&#xD;
         15. Agreed not to undergo any other procedure on their face during their participation in&#xD;
             the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant, intending to become pregnant during the course of study, less than 3 months&#xD;
             postpartum or less than 3 months after completion of breastfeeding&#xD;
&#xD;
          2. Known hypersensitivity or contraindications to anaesthetic agents including lidocaine&#xD;
             and its derivatives&#xD;
&#xD;
          3. Participation in a study of another device or drug within three months prior to&#xD;
             enrolment or during the study.&#xD;
&#xD;
          4. Presence of open wounds or lesions in the area&#xD;
&#xD;
          5. Extensive scarring or tattoos in areas to be treated.&#xD;
&#xD;
          6. Having other pigmentation disorder&#xD;
&#xD;
          7. Having an excessive underlying vascular condition (e.g. dense network of capillaries).&#xD;
&#xD;
          8. Suffering from current or history of significant skin conditions in the treated area&#xD;
             that could interfere with the evaluation (i.e. infection, dermatitis, or rash on their&#xD;
             face) or requires the use of interfering topical or systemic therapy.&#xD;
&#xD;
          9. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning&#xD;
             during the study.&#xD;
&#xD;
         10. Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in&#xD;
             the treated area, unless treatment is conducted following a prophylactic regimen&#xD;
&#xD;
         11. Subjects who are opposed to possible damage to the hair follicles with possible loss&#xD;
             of hair in the treatment area&#xD;
&#xD;
         12. Laser or medium/deep chemical peel, or surgery, or filler treatments using collagen,&#xD;
             hyaluronic acid, or any other material at area of treatment, within 6 months of&#xD;
             initial treatment or during the course of the study.&#xD;
&#xD;
         13. IPL or superﬁcial chemical peel within the previous 1 month&#xD;
&#xD;
         14. Topical therapy with retinoids, imiquimod, 5-ﬂuorouracil, ingenol mebutate,&#xD;
             diclofenac, alpha-hydroxy acids, or salicylic acids within the previous 1 month.&#xD;
&#xD;
         15. Currently using topical retinoid, hydroquinone or corticosteroid or whitening cream&#xD;
             such as alpha arbutin, azelaic acid, kojic acid ascorbic acid or any cosmetics within&#xD;
             2 weeks&#xD;
&#xD;
         16. Lightening oral medication (hydroquinone, tranexamic acid), isotretinoid (or&#xD;
             retinoid), light-sensitive medication, or steroids in the last 6 months&#xD;
&#xD;
         17. History of keloid scarring, hypertrophic scarring, or of abnormal wound healing.&#xD;
&#xD;
         18. History of connective tissue diseases such as systemic lupus erythematosus or&#xD;
             scleroderma&#xD;
&#xD;
         19. Active leukoplakia, eczema, or psoriasis in the treatment area&#xD;
&#xD;
         20. History of post inflammatory pigmentary disorders, particularly a tendency for hyper-&#xD;
             or hypo-pigmentation.&#xD;
&#xD;
         21. History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins&#xD;
             or photodermatosis.&#xD;
&#xD;
         22. Has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines,&#xD;
             etc.) within a timeframe where photosensitization from these drugs may still be&#xD;
             present&#xD;
&#xD;
         23. History of skin cancer in the treatment area&#xD;
&#xD;
         24. Significant concurrent illness or any disease state that in the opinion of the&#xD;
             Investigator would interfere with the treatment or healing process&#xD;
&#xD;
         25. History of immunosuppression/immune deficiency disorders (including HIV infection or&#xD;
             AIDS) or currently using immunosuppressive medications.&#xD;
&#xD;
         26. Having a known anticoagulative or thromboembolic condition or taking anticoagulation&#xD;
             medications one week prior to and during the treatment course (to allow inclusion,&#xD;
             temporary cessation of use as per the subject's physician's discretion).&#xD;
&#xD;
         27. History of hormonal therapy in the last 3 months (e.g., estrogen, progesterone, or&#xD;
             oral contraceptive)&#xD;
&#xD;
         28. As per the Investigator's discretion, any physical or mental condition which might&#xD;
             make it unsafe for the subject to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hackensack University Medical Center - Skin Laser &amp; Surgery Specialists Of NY &amp; NJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hackensack University Medical Center - Skin Laser &amp; Surgery Specialists Of NY &amp; NJ</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

